加载中
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
前收盘价
US$17.13
−US$0.46 · -2.62%
盘前
US$17.11
−US$0.02 · -0.12%
10月13日 6:23 ET
盘中时间采用ET。市场数据可能有所延迟。
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
日内区间
当前US$17.13
52周区间
当前US$17.13
盘中时间采用ET。市场数据可能有所延迟。
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
日内区间
当前US$17.13
52周区间
当前US$17.13
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | — | 58.32万 USD | 133.77万 USD |
| 毛利 | — | — | — | 58.32万 USD | 133.77万 USD |
| 研究与开发 | 5.38亿 USD | 1.32亿 USD | 4.55亿 USD | 4301.46万 USD | 6311.52万 USD |
| 销售、一般及管理费用 | 5.57亿 USD | 4834.53万 USD | 2374.08万 USD | 2212.23万 USD | 1745.96万 USD |
| 营业费用 | 10.94亿 USD | 1.81亿 USD | 4.78亿 USD | 6021.67万 USD | 6506.97万 USD |
| 利息收入 | 1550.1万 USD | 1346.6万 USD | 1040.3万 USD | 151.3万 USD | — |
| 利息支出 | — | 868.6万 USD | 1646.1万 USD | 440.1万 USD | 20.83万 USD |
| 折旧和摊销 | 14.6万 USD | 8.9万 USD | 19.8万 USD | 126.3万 USD | 245.5万 USD |
| 营业利润 | −10.94亿 USD | −1.81亿 USD | −4.78亿 USD | −5963.35万 USD | −6373.2万 USD |
| 净利润 | −10.8亿 USD | −1.77亿 USD | −4.82亿 USD | −6517万 USD | −6551.85万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$29.33
上涨空间 71.22%报告持有此股票敞口的交易所交易基金。
State Street SPDR S&P Biotech ETFXBI6295.36万0.64%103.03亿 USD0.35%US$151.4-1.54%
Vanguard Morningstar Total Stock Market ETFVTI5060.97万0.00%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard Morningstar Small-Cap ETFVB3646.74万0.02%1853亿 USD0.03%US$288.16-0.46%
Vanguard Extended Market ETFVXF2459.88万0.03%954亿 USD0.05%US$233.52-0.63%
Vanguard Morningstar Small-Cap Value ETFVBR2317.06万0.03%682亿 USD0.05%US$234.71+0.12%
iShares Biotechnology ETFIBB2081.82万0.19%108.2亿 USD0.44%US$204.26-1.08%
iShares Russell Mid-Cap Growth ETFIWP1375.15万0.07%200.95亿 USD0.23%US$140.99-1.47%
iShares Russell Mid-Cap ETFIWR1011.1万0.02%567.65亿 USD0.18%US$109.47-0.32%State Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Extended Market ETFVXFVanguard Morningstar Small-Cap Value ETFVBRiShares Biotechnology ETFIBBiShares Russell Mid-Cap Growth ETFIWPiShares Russell Mid-Cap ETFIWRAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
